- Home
- API vs BCYC Comparison
API vs BCYC Comparison
Compare API & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | API | BCYC |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.0M | 291.8M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | API | BCYC |
|---|---|---|
| Price | $4.09 | $3.94 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $13.90 |
| AVG Volume (30 Days) | 266.3K | ★ 335.1K |
| Earning Date | 05-26-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.46 | N/A |
| Revenue Next Year | $12.87 | N/A |
| P/E Ratio | $92.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.14 | $3.75 |
| 52 Week High | $5.50 | $9.16 |
Technical Indicators
Market Signals| Indicator | API | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 52.90 | 41.22 |
| Support Level | $4.01 | N/A |
| Resistance Level | $4.16 | $4.52 |
| Average True Range (ATR) | 0.11 | 0.15 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 98.28 | 27.97 |
Price Performance
Historical ComparisonAbout API Agora Inc.
Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.